Caidya and Simbec-Orion Merge to Form Global CRO Platform
Caidya integrates with Simbec-Orion to bridge early-phase science and global clinical execution for biopharma clients.
Caidya announced a strategic integration with Simbec-Orion on Wednesday, creating a differentiated contract research organization platform designed to close the gap between early scientific insights and full-scale global clinical trial execution. The combined entity will serve innovative biopharmaceutical companies across Europe, the Americas, Asia-Pacific, and China, delivering specialized capabilities in the regions where drug development decisions matter most.
The merger brings together complementary strengths that neither organization held independently. Simbec-Orion contributes deep early-phase clinical pharmacology expertise alongside a strong track record in complex oncology and rare disease trials, while Caidya adds the infrastructure and operational footprint needed to scale studies without sacrificing focus or accountability.
Read more Moburst Acquires Hyperzon to Expand Amazon Marketing Capabilities →
Together, the integrated organization offers a continuous development pathway spanning first-in-human studies through both healthy volunteer and patient populations, all the way to product registration. That end-to-end continuity is intended to help sponsors make critical go/no-go decisions earlier in the research lifecycle, potentially compressing timelines and reducing redundant handoffs between vendors.
The combined platform also promises the responsiveness and close collaboration typically associated with specialist CROs, even as its geographic reach now rivals larger global players. With nearly five decades of combined experience supporting biopharmaceutical innovation and established footholds across multiple continents, the merged company positions itself as a full-lifecycle research partner rather than a point solution.
Continue reading at BusinessWire.
